Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Autoimmune Gastrointestinal Dysmotility Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size for autoimmune gastrointestinal dysmotility has been experiencing consistent growth in the most recent years. The market, which is projected to expand from $1.73 billion in 2024 to $1.82 billion in 2025, will do so at a compound annual growth rate (CAGR) of 5.0%. The growth witnessed during the historic period can be tied to a rise in ignorance about rare diseases, an increase in inadequate diagnostic procedures, a surge in instances of misdiagnosis with other gastro-intestinal disorders, a lack of targeted therapies, and significant delays in research advancement.
The market size for autoimmune gastrointestinal dysmotility is slated for robust expansion in the upcoming years. Forecasts predict a growth to $2.37 billion by 2029, with a compound annual growth rate (CAGR) of 6.9%. Factors contributing to the growth during the forecast period include the increasing incidence of autoimmune diseases, enhancements in diagnostic techniques, expansion in healthcare spending, the rise in rare disease registries, and improved medical practitioner education. Key trends for the forecast period involve advancements in diagnostic technology, breakthroughs in immunotherapy, progress in neurogastroenterology research, research, and development of motility modulators, along with personalizing treatment strategies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Autoimmune Gastrointestinal Dysmotility Market?
The growth of the autoimmune gastrointestinal dysmotility market is anticipated to surge due to the ever-increasing incidence of autoimmune disorders. These medical conditions happen when the body’s immune system unintentionally attacks its own healthy cells, tissues, or organs instead of shielding them from infections and alien substances. A blend of genetic susceptibility and environmental instigator is the principal reason for the increased incidence of autoimmune disorders. This mix perturbs the regulation of the immune system and augments the chances of the body targeting its own tissues. Autoimmune gastrointestinal dysmotility assists in detecting and controlling autoimmune disorders through illustrating immune-mediated harm to the enteric nervous system, tying gastrointestinal symptoms to systemic autoimmune activity. For instance, a survey study conducted by Versorgungsatlas.de, a Germany-based organization, in November 2024 found that out of 73,241,305 surveyed in 2022, about 6,304,340 were diagnosed with a minimum of one autoimmune disease, resulting in a raw prevalence rate of 8.61. Accordingly, the ascending occurrence of autoimmune disorders is stimulating the growth of the autoimmune gastrointestinal dysmotility market.
Which Key Market Segments Comprise the Autoimmune Gastrointestinal Dysmotility Market and Drive Its Revenue Growth?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp
Which Areas Are Leading Regions in the Autoimmune Gastrointestinal Dysmotility Market Expansion Across the Globe?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theAutoimmune Gastrointestinal Dysmotility Market Over the Coming Years?
Leading firms in the autoimmune gastrointestinal dysmotility market are directing their efforts towards forging strategic alliances to deliver digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. These partnerships not only enhance care but also offer unified, predominantly virtual healthcare with multidisciplinary teams, thus bolstering symptom management, access to care, and cost efficiency. To illustrate, in March 2022, Solera Health, a digital health firm from the US, entered into a partnership with Oshi Health, a virtual gastrointestinal care company, and Vivante Health, another US-based digital health organization. This partnership will facilitate the delivery of enhanced digital therapy solutions to assist in the management and treatment of autoimmune gastrointestinal dysmotility. The aim of this collaboration is to augment patient access to specialized care and boost overall treatment efficiency for individuals suffering from gastrointestinal disorders.
View the full report here:
How Is the Autoimmune Gastrointestinal Dysmotility Market Conceptually Defined?
Autoimmune gastrointestinal dysmotility (AGID) is a rare disorder where the immune system attacks the nerves controlling digestive tract movement. This disorder leads to slowed or abnormal motility, causing symptoms such as nausea, bloating, constipation, or intestinal blockage. Autoimmune gastrointestinal dysmotility (AGID) is often associated with autoimmune conditions or may occur as a paraneoplastic syndrome.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24160
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
